30 Participants Needed

Adaptive Radiotherapy + Hormone Therapy for Prostate Cancer

AB
Brian C Baumann profile photo
Hiram A Gay, M.D. profile photo
Overseen ByHiram A Gay, M.D.
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Washington University School of Medicine
Must be taking: Androgen deprivation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications for this trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had systemic chemotherapy within 3 years prior to treatment start, and you must not have prior androgen deprivation therapy unless it started within 60 days before treatment. It's best to discuss your current medications with the trial team.

What data supports the idea that Adaptive Radiotherapy + Hormone Therapy for Prostate Cancer is an effective treatment?

The available research shows that adding stereotactic ablative radiotherapy (SABR) to standard treatment for prostate cancer can slow the disease's growth and improve survival rates. For instance, the ORIOLE trial found that SABR slowed disease progression in men with hormone-sensitive metastatic prostate cancer, allowing them to delay further hormone therapy. Additionally, the SABR-COMET trial reported a significant improvement in overall survival for patients treated with SABR. These findings suggest that combining adaptive radiotherapy with hormone therapy can be an effective treatment for prostate cancer.12345

What safety data exists for adaptive radiotherapy and hormone therapy in prostate cancer treatment?

The safety data for adaptive radiotherapy, including stereotactic body radiation therapy (SBRT) and stereotactic ablative radiotherapy (SABR), combined with hormone therapy (ADT) for prostate cancer, indicates that these treatments are generally safe and effective. In a study of 400 patients treated with SABR, no severe late adverse effects were observed, and only a small percentage experienced acute reactions. Another study comparing SBRT to conventional therapy found SBRT to be a promising non-invasive alternative with potential benefits in quality of life and reduced toxicity. Long-term data from a 7-year study also supports the safety and effectiveness of SBRT, showing excellent disease control with manageable toxicity levels.678910

Is Adaptive Stereotactic Body Radiation Therapy a promising treatment for prostate cancer?

Yes, Adaptive Stereotactic Body Radiation Therapy (SBRT) is a promising treatment for prostate cancer. It can improve survival, delay further cancer spread, and slow down cancer growth, allowing patients to postpone additional treatments.123411

What is the purpose of this trial?

This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.

Research Team

AB

Amit Bhatt, M.D., Ph.D.

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

Men over 18 with high-risk or unfavorable intermediate-risk prostate cancer, who haven't had prior treatments like chemotherapy or radical prostatectomy in the last 3 years. They should have an ECOG performance status ≤1, no evidence of metastatic disease, and be able to start hormone therapy within 60 days of radiation treatment.

Inclusion Criteria

Able to understand and willing to sign an IRB approved written informed consent document
Able to complete relevant patient-reported quality-of-life questionnaires
My condition is classified as unfavorable intermediate-risk with specific risk factors.
See 4 more

Exclusion Criteria

I have undergone major prostate cancer treatment.
My scans show cancer has spread to my lymph nodes or other parts of my body.
AUA urinary symptom score ≥ 20
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Adaptive stereotactic body radiotherapy (SBRT) with simultaneous integrated boosts to the prostate and MR-detected nodules

5 weeks
5 visits (in-person)

Androgen Deprivation Therapy (ADT)

ADT administered according to institutional standard, with a minimum of 4 months for intermediate-risk and 1 year for high-risk disease

4-24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments of biochemical recurrence and overall survival

60 months
Every 3 months until month 24, then as needed

Treatment Details

Interventions

  • Adaptive Stereotactic Body Radiation Therapy
  • Androgen deprivation therapy
Trial Overview The trial is testing a new way to deliver radiation (Ethos Varian system) that adapts to the shape of the tumor daily, combined with hormone therapy. It aims to see if this method can target tumors more precisely while reducing side effects.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Adaptive stereotactic body radiotherapy (SBRT)Experimental Treatment3 Interventions
* Treatment consists of adaptive dose-escalated stereotactic body radiotherapy (SBRT) to the pelvic nodes to 25 Gy in 5 once or twice weekly fractions with simultaneous integrated boosts (SIB) to the prostate and proximal seminal vesicles to 36.25 Gy in 5 fractions (full seminal vesicles if involved), to the prostate to 40 Gy in 5 fractions, and to the involved MR-detected nodule(s) to up to 50 Gy in 5 fractions. * Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Unfavorable Intermediate-risk Disease: Patients should receive a minimum of 4 months of ADT. Patients can receive longer duration of ADT at the discretion of the treating physician. High-risk disease: Patients should receive a minimum of 1 year of ADT. Patients can receive up to 2 years of ADT at the discretion of the treating physician.

Adaptive Stereotactic Body Radiation Therapy is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
🇺🇸
Approved in United States as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
🇨🇦
Approved in Canada as SBRT for:
  • Prostate cancer
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Varian Medical Systems

Industry Sponsor

Trials
63
Recruited
3,700+

Dow R. Wilson

Varian Medical Systems

Chief Executive Officer since 2012

MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University

Dr. Deepak Khuntia

Varian Medical Systems

Chief Medical Officer since 2020

MD from the University of Cambridge, PhD from the University of Leicester

Findings from Research

In a study involving 20 prostate cancer patients treated with Adaptive Stereotactic Body Radiotherapy (SBRT), the delivered dose was confirmed to be adequate, ensuring that the target area received at least 95% of the prescribed dose while minimizing exposure to surrounding organs.
The study demonstrated that both the daily re-computed doses and cumulative doses were consistent, indicating that the online MRI guidance effectively maintained treatment accuracy despite potential prostate motion during the longer session times.
Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time.Ruggieri, R., Rigo, M., Naccarato, S., et al.[2021]
In a study of 87 men with oligometastatic prostate cancer treated with stereotactic ablative radiotherapy (SABR), the median disease-free survival (DMFS) was 21.8 months for hormone-sensitive patients, indicating a significant benefit from this treatment.
Combining SABR with short-term androgen-deprivation therapy improved both biochemical progression-free survival (bPFS) and DMFS in patients with oligorecurrent hormone-sensitive prostate cancer, suggesting a potential strategy for enhancing treatment outcomes.
Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.Mercier, C., Claessens, M., De Troyer, B., et al.[2022]
The phase II ORIOLE trial found that adding stereotactic ablative radiotherapy (SABR) to standard treatment significantly slowed disease progression over 6 months in men with hormone-sensitive metastatic prostate cancer, allowing for a delay in androgen deprivation therapy.
Further research is necessary to explore whether SABR, either alone or in combination with immunotherapies, can effectively prevent the development of new metastases in these patients.
Intense Radiotherapy Slows Prostate Cancer Growth.[2021]

References

Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. [2021]
Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer. [2022]
Intense Radiotherapy Slows Prostate Cancer Growth. [2021]
Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer. [2022]
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. [2022]
Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients [2020]
Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. [2022]
Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. [2022]
A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). [2021]
Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study. [2022]
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security